---
title: "REGENXBIO Announces Positive Topline Results from Pivotal Phase III AFFINITY DUCHENNE® Study of RGX-202 | RGNX Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286403513.md"
description: "REGENXBIO Announces Positive Topline Results from Pivotal Phase III AFFINITY DUCHENNE® Study of RGX-202 | RGNX Stock News"
datetime: "2026-05-14T03:01:10.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286403513.md)
  - [en](https://longbridge.com/en/news/286403513.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286403513.md)
---

# REGENXBIO Announces Positive Topline Results from Pivotal Phase III AFFINITY DUCHENNE® Study of RGX-202 | RGNX Stock News

REGENXBIO Announces Positive Topline Results from Pivotal Phase III AFFINITY DUCHENNE® Study of RGX-202 | RGNX Stock News

### Related Stocks

- [RGNX.US](https://longbridge.com/en/quote/RGNX.US.md)

## Related News & Research

- [REGENXBIO Reports First Quarter 2026 Financial Results and Operational Highlights | RGNX Stock News](https://longbridge.com/en/news/286405286.md)
- [RegenXBio Advances RGX-202 With Positive Phase III Results](https://longbridge.com/en/news/286412399.md)
- [REGENXBIO Advances Duchenne Gene Therapy Toward Accelerated Approval](https://longbridge.com/en/news/286443456.md)
- [ISG to Study Supply Chain Service Providers | III Stock News](https://longbridge.com/en/news/287079576.md)
- [Regenxbio's muscle disorder therapy meets main goal in late-stage study](https://longbridge.com/en/news/286406339.md)